• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.

作者信息

Xiang N, James M, Walters S, Bamford A, Foster C

机构信息

Department of Paediatric Infectious Diseases, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.

出版信息

HIV Med. 2014 Nov;15(10):635-6. doi: 10.1111/hiv.12180.

DOI:10.1111/hiv.12180
PMID:25334035
Abstract
摘要

相似文献

1
Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.从基于洛匹那韦的抑制性疗法转换为增强型达芦那韦或阿扎那韦治疗的儿科患者血清胆固醇改善情况：一项18个月的回顾性研究
HIV Med. 2014 Nov;15(10):635-6. doi: 10.1111/hiv.12180.
2
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.阿扎那韦/利托那韦或达芦那韦/利托那韦引起的早期脂质变化。
HIV Med. 2014 Jul;15(6):330-8. doi: 10.1111/hiv.12121. Epub 2014 Jan 12.
3
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.与依非韦伦、利托那韦增强洛匹那韦和利托那韦增强达芦那韦相比，利托那韦增强阿扎那韦的暴露与肾结石发生率的增加相关。
AIDS. 2011 Aug 24;25(13):1671-3. doi: 10.1097/QAD.0b013e32834a1cd6.
4
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.在血浆病毒血症检测不到的HIV感染患者中用阿扎那韦替换洛匹那韦的疗效和安全性：SLOAT试验的最终结果
J Antimicrob Chemother. 2008 Jan;61(1):200-5. doi: 10.1093/jac/dkm413. Epub 2007 Nov 13.
5
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].所有增强型蛋白酶抑制剂都一样吗？接受过治疗的患者也能从洛匹那韦/利托那韦中获益。
MMW Fortschr Med. 2003 Dec 11;145(50):61.
6
[Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].[西班牙初治的1型人类免疫缺陷病毒感染患者中，达芦那韦/利托那韦与其他蛋白酶抑制剂的成本效益比较分析]
Enferm Infecc Microbiol Clin. 2013 Aug-Sep;31(7):430-6. doi: 10.1016/j.eimc.2012.11.001. Epub 2012 Dec 20.
7
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.在人类免疫缺陷病毒患者中换用基于阿扎那韦-利托那韦的高效抗逆转录病毒疗法后的降脂疗效及安全性
Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.
8
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.美国初治人类免疫缺陷病毒感染患者中阿扎那韦-利托那韦与洛匹那韦-利托那韦的成本效果比较。
J Med Econ. 2011;14(2):167-78. doi: 10.3111/13696998.2011.554932. Epub 2011 Feb 2.
9
High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.无症状患者尿中阿扎那韦和达芦那韦浓度高和出现结晶尿。
J Antimicrob Chemother. 2013 Aug;68(8):1850-6. doi: 10.1093/jac/dkt125. Epub 2013 Apr 18.
10
[Efficacy of atazanavir in treatment-naive patients].[阿扎那韦在初治患者中的疗效]
Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:9-13. doi: 10.1016/S0213-005X(08)76614-X.

引用本文的文献

1
Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.接受抗逆转录病毒治疗的越南HIV感染者的血脂异常与心血管疾病
Glob Health Med. 2020 Feb 29;2(1):39-43. doi: 10.35772/ghm.2019.01035.
2
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.在使用较老的蛋白酶抑制剂治疗的围生期感染 HIV 的儿童和青少年中，换用增效后的阿扎那韦或达芦那韦后血脂改善：儿科 HIV/AIDS 队列研究的结果。
HIV Med. 2018 Mar;19(3):175-183. doi: 10.1111/hiv.12566. Epub 2017 Nov 21.
3
Serum lipid and glucose profiles in HIV-positive Nigerian children.
尼日利亚HIV阳性儿童的血脂和血糖情况
J Virus Erad. 2017 Jul 1;3(3):157-162. doi: 10.1016/S2055-6640(20)30335-6.
4
Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.在临床实践中，转换为利托那韦增强与未增强阿扎那韦联合雷特格韦的双药治疗可带来相似的疗效和安全性结局。
PLoS One. 2016 Oct 31;11(10):e0164240. doi: 10.1371/journal.pone.0164240. eCollection 2016.
5
Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.阿托伐他汀在感染人类免疫缺陷病毒的高脂血症儿童、青少年及青年中的安全性和有效性
Pediatr Infect Dis J. 2017 Jan;36(1):53-60. doi: 10.1097/INF.0000000000001352.
6
Darunavir: A Review in Pediatric HIV-1 Infection.达芦那韦：儿童HIV-1感染的综述
Paediatr Drugs. 2015 Oct;17(5):411-21. doi: 10.1007/s40272-015-0146-0.
7
Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.儿科艾滋病治疗欧洲网络（PENTA）2015 年治疗儿科 HIV-1 感染指南：优化健康，为成年生活做准备。
HIV Med. 2018 Jan;19(1):e1-e42. doi: 10.1111/hiv.12217. Epub 2015 Feb 3.
8
Virtual support for paediatric HIV treatment decision making.对儿科艾滋病治疗决策的虚拟支持。
Arch Dis Child. 2015 Jun;100(6):527-31. doi: 10.1136/archdischild-2014-307019. Epub 2014 Dec 30.